{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:14:11Z","timestamp":1772795651374,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":2152,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.rmed.2007.06.002","type":"journal-article","created":{"date-parts":[[2007,7,21]],"date-time":"2007-07-21T07:24:06Z","timestamp":1185002646000},"page":"2065-2075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study"],"prefix":"10.1016","volume":"101","author":[{"given":"Alexander G.","family":"Chuchalin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla N.","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Krug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.B.","family":"Luursema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Woessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"van As","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2007.06.002_bib1","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January 1995 (updated 2006; accessed 24 January 2007). Available from: \u3008http:\/\/www.ginasthma.com\u3009."},{"key":"10.1016\/j.rmed.2007.06.002_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/thorax.58.7.580","article-title":"Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: cochrane systematic review and meta-analysis","volume":"58","author":"Ram","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2007.06.002_bib3","article-title":"Short-acting beta2 agonists for stable chronic obstructive pulmonary disease","volume":"CD001495","author":"Sestini","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl.","key":"10.1016\/j.rmed.2007.06.002_bib4","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1067\/mai.2002.129966","article-title":"Adverse effects of beta-agonists","volume":"110","author":"Sears","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2007.06.002_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/jpet.105.098251","article-title":"In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action","volume":"317","author":"Battram","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 49","key":"10.1016\/j.rmed.2007.06.002_bib6","article-title":"Single dose indacaterol, a novel 24-h \u03b22-agonist, is well tolerated in patients with mild asthma [abstract]","volume":"26","author":"Duvauchelle","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2007.06.002_bib7","unstructured":"World Medical Association. Ethical principles for medical research involving human subjects (1964 and subsequent revisions; accessed 24 January 2007). Available from: \u3008http:\/\/www.wma.net\/e\/policy\/b3.htm\u3009."},{"key":"10.1016\/j.rmed.2007.06.002_bib8","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January 1995 (updated 2002; accessed 24 January 2007). Available from: \u3008http:\/\/www.ginasthma.com\u3009."},{"key":"10.1016\/j.rmed.2007.06.002_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"10.1016\/j.rmed.2007.06.002_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1183\/09031936.00060006","article-title":"Indacaterol, a novel inhaled \u03b22-agonist, provides sustained 24-h bronchodilation in asthma","volume":"29","author":"Beeh","year":"2007","journal-title":"Eur Respir J"},{"issue":"Suppl. 6","key":"10.1016\/j.rmed.2007.06.002_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2165\/00003495-199600526-00004","article-title":"Compliance and outcomes in patients with asthma","volume":"52","author":"Cochrane","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2007.06.002_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/pgmj.2003.014936","article-title":"Management of paediatric asthma","volume":"80","author":"Grigg","year":"2004","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.rmed.2007.06.002_bib13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/thx.49.8.771","article-title":"Systemic effects of salbutamol and salmeterol in patients with asthma","volume":"49","author":"Bennett","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2007.06.002_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/thx.52.5.458","article-title":"Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects","volume":"52","author":"Bennett","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2007.06.002_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2125.1992.tb04049.x","article-title":"Dose-response study with high-dose inhaled salmeterol in healthy subjects","volume":"33","author":"Maconochie","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2007.06.002_bib16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1183\/09031936.93.06020204","article-title":"A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol","volume":"6","author":"Bremner","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2007.06.002_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s002280050435","article-title":"The extrapulmonary effects of increasing doses of formoterol in patients with asthma","volume":"54","author":"Burgess","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2007.06.002_bib18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1378\/chest.99.6.1367","article-title":"The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations","volume":"99","author":"Maesen","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2007.06.002_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1183\/09031936.98.12030573","article-title":"Tolerability to high doses of formoterol and terbutaline via turbuhaler for 3 days in stable asthmatic patients","volume":"12","author":"Totterman","year":"1998","journal-title":"Eur Respir J"},{"issue":"Suppl. 50","key":"10.1016\/j.rmed.2007.06.002_bib20","article-title":"Indacaterol, a novel once-daily \u03b22-agonist, is well tolerated in persistent asthma","volume":"28","author":"Yang","year":"2006","journal-title":"Eur Respir J"},{"issue":"Suppl. 50","key":"10.1016\/j.rmed.2007.06.002_bib21","article-title":"Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma","volume":"28","author":"Pascoe","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2007.06.002_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1164\/ajrccm\/140.5.1222","article-title":"Cardiovascular response to acute airway obstruction and hypoxia","volume":"140","author":"Chapman","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2007.06.002_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2125.1995.tb04552.x","article-title":"Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers","volume":"40","author":"Kiely","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2007.06.002_bib24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/thx.47.10.814","article-title":"Cardiovascular effects of fenoterol under conditions of hypoxaemia","volume":"47","author":"Bremner","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2007.06.002_bib25","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0002-9149(99)00586-X","article-title":"Asthma and the risk of cardiac events in the Long QT syndrome. Long QT Syndrome Investigative Group","volume":"84","author":"Rosero","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rmed.2007.06.002_bib26","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199210223271703","article-title":"Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma","volume":"327","author":"Cheung","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2007.06.002_bib27","first-page":"529","article-title":"Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists","volume":"56","author":"van der Woude","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2007.06.002_bib28","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1056\/NEJM199211123272004","article-title":"A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma","volume":"327","author":"Pearlman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2007.06.002_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1378\/chest.129.1.27","article-title":"Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo","volume":"129","author":"Wolfe","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2007.06.002_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2125.1994.tb04261.x","article-title":"Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?","volume":"37","author":"Maconochie","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2007.06.002_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/thx.50.5.497","article-title":"Subsensitivity of bronchodilator and systemic beta2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients","volume":"50","author":"Newnham","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2007.06.002_bib32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1183\/09031936.00032806","article-title":"Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi","volume":"29","author":"Naline","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2007.06.002_bib33","article-title":"Safety, tolerability and efficacy of indacaterol, a novel once-daily \u03b22- agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial","volume":"September 30","author":"Beier","year":"2006","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611107002582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611107002582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:36:21Z","timestamp":1760610981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611107002582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0954611107002582"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2007.06.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2007.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}